Novel treatment approach for bladder pain using a herpes simplex virus vector reported

March 14, 2013
©2013 Mary Ann Liebert, Inc., publishers

Severe chronic pain associated with conditions such as bladder pain syndrome/interstitial cystitis often require the use of opioid medication, with the risk of dependency and serious adverse reactions. An alternative treatment strategy increases the levels of a naturally occurring painkiller in and around the nerves that deliver pain signals to the bladder. This new therapeutic approach is described in an article in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

Hitoshi Yokoyama, MD and colleagues from University of Pittsburgh School of Medicine (PA), Shinshu University School of Medicine (Matsumoto, Japan), and Diamyd (Pittsburgh, PA) describe a in which they inject directly into the bladder wall the gene for enkephalin, an opioid compound produced by the human body. The gene is transported into the via a vector that is incapable of replication.

In the article "Effects of Herpes Simplex -Mediated Enkephalin Gene Therapy on Bladder Overactivity and Nociception," the authors demonstrate high levels of enkephalin gene expression in the treated rats and significantly lower measures of pain compared to untreated animals when exposed to stimuli intended to induce bladder irritation. The researchers note that a similar gene therapy delivery vector carrying an enkephalin gene has been used in clinical studies in human patients to treat cancer-related pain, and was shown to be well tolerated and safe and to provide substantial pain relief.

"This is a very innovative application of Herpes Simplex Virus gene therapy in the treatment of a common and painful clinical problem that otherwise requires chronic use of narcotics," says James M. Wilson, MD, PhD, Editor-in-Chief, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.

Explore further: Targeted gene therapy enhances treatment for Pompe disease

More information: The article is available free on the Human Gene Therapy website at http://www.liebertpub.com/hum.

Related Stories

Targeted gene therapy enhances treatment for Pompe disease

June 25, 2012

Gene therapy to replace the protein missing in Pompe disease can be effective if the patient's immune system does not react against the therapy. Targeted delivery of the gene to the liver, instead of throughout the body,suppresses ...

Recommended for you

How our cells use mother's and father's genes

September 28, 2016

Researchers at Karolinska Institutet and Ludwig Institute for Cancer Research have characterized how and to what degree our cells utilize the gene copies inherited from our mother and father differently. At a basic level ...

Questions, concerns about 'three-parent' baby

September 28, 2016

The surprise announcement that a healthy baby boy was born from a new technique mixing the DNA of two women and a man raises as many questions—scientific and ethical—as it settles, experts said Wednesday.

Regulatory RNA essential to DNA damage response

September 26, 2016

Stanford researchers have found that a tumor suppressor known as p53 is stabilized by a regulatory RNA molecule called DINO. The interaction helps a cell respond to DNA damage and may play a role in cancer development and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.